AMEX · IBO

Impact BioMedical, Inc.

$0.44 +$0.01 (+2.25%) 1D After hours

Key Metrics

$46.40M
Market cap
P/E · TTM
$39.00K
Revenue · TTM
−$12.86M
Net income
EPS · TTM $-1.07
Dividend yield
Free cash flow
Beta · 1Y -0.12
EBITDA · TTM −$14.31M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 22
    From its Mar 20 high, the share price fell 45%.

    Peak close $0.78 on Mar 20; trough close $0.43 on Jul 22. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -45%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 20
    The stock moved +68.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 20
  • Mar 5
    The stock moved +55.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$46.40M
Enterprise value
Shares outstanding107.8M
52-wk range$0.37 – $0.83
Avg volume · 20D3.0M
Net cash
Book value / share$0.95
IndustryPharmaceutical Preparations
ExchangeAMEX
About Impact BioMedical, Inc.
IPO dateSep 16, 2024
Employees8

Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1,189.63
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating -39,630.8%
Net -32,969.2%
FCF
ROE / ROIC -163.6% · —

Financial Health

Current ratio0.22
Quick ratio0.19
Debt / equity
Debt / EBITDA
Net cash
Working capital−$1.31M

Cash Flow · TTM

Operating CF −$1.67M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

4.4
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings